The microbiome is closely related to the development of cancer, and it is feasible to modulate the microbiome for cancer therapy. Strategies based on the modulation of the microbiome, such as probiotic therapy and fecal microbiota transplantation (FMT), have achieved certain results in cancer therapy. However, poor targeting and low survival rate of the microbiome limited their further application in cancer therapy. Nanomaterials such as liposomes and micelles are widely used as carriers for drug delivery due to their good biocompatibility and stability. The latest evidence indicates that some nanomedicines can reverse cancer-promoting effects (such as promoting cell proliferation and accelerating tissue inflammation) by eliminating cancer-related microbiota, or increase the proportion of beneficial bacteria, which further enhance the production of beneficial metabolites, facilitate immune cell infiltration, and reshape the tumor microenvironment (TME), thereby inhibit tumor growth. Thus, it is promising to enhance the efficacy of cancer therapy by regulating microbiota through nanomedicines. This review highlights recent advances in the integration of nanomedicine and microbiota modulation for cancer treatment, aiming to provide insights into the design of innovative therapeutic strategies and broaden treatment options for cancer patients.
15 November 2024 in International Journal of Pharmaceutics
Preeclampsia (PE), a pregnancy-specific disorder characterized by hypertension and placental dysfunction, remains a leading cause of maternal and fetal morbidities worldwide. Recent advances in nanomedicine offer promising therapeutic strategies by targeting placental pathologies. Studies have demonstrated that in PE mouse models, the regulation of key disease-related genes (such as sFlt1 and VEGF) using siRNA- or mRNA-loaded carriers (eg, lipid nanoparticles, exosomes, or elastin-like polypeptides) can effectively alleviate PE symptoms. This review summarizes the progress in nanoparticle-based therapies for PE, discusses challenges such as scalability and clinical translation, and highlights the potential of nanomedicine to revolutionize PE management.
As a typical solid tumor, breast cancer is characterized by a tumor microenvironment featuring hypoxia, acidosis, and highly reductive conditions. These factors contribute to treatment resistance (e.g., chemoresistance) through various mechanisms, thereby diminishing therapeutic efficacy. Calcium peroxide (CaO2) can generate multiple bioactive molecules (metal ions, H2O2, O2, and OH−) in acidic or neutral environment, making it a promising biomaterial for cancer therapy. Recently, breast cancer has been extensively targeted using CaO2 nanoparticles in both cellular and murine models. In this review, we first provide a summary of strategies employing CaO2 nanomedicine-based breast cancer therapies, then discuss the obstacles and development directions of CaO2 application in breast cancer therapy.
28 October 2024 in International Journal of Pharmaceutics